Spine Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain byTim AllenDecember 2, 2025
Regulatory Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee byJosh SandbergOctober 28, 2025
Extremities Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy byJosh SandbergOctober 21, 2025
Financial Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program byJosh SandbergMay 7, 2024
Financial Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results byJosh SandbergFebruary 29, 2024
Extremities Regulatory Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures byJosh SandbergMarch 29, 2023
Recon Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty byJosh SandbergSeptember 7, 2022
Biologics Recon Spine Sports Medicine Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes byJosh SandbergJuly 2, 2020
Financial Regulatory Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System byJosh SandbergApril 9, 2019
